title: The prototoxin LYPD6B modulates heteromeric α3β4-containing nicotinic acetylcholine receptors, but not α7 homomers.
abstract: Prototoxins are a diverse family of membrane-tethered molecules expressed in the nervous system that modulate nicotinic cholinergic signaling, but their functions and specificity have yet to be completely explored. We tested the selectivity and efficacy of leukocyte antigen, PLAUR (plasminogen activator, urokinase receptor) domain-containing (LYPD)-6B on α3β4-, α3α5β4-, and α7-containing nicotinic acetylcholine receptors (nAChRs). To constrain stoichiometry, fusion proteins encoding concatemers of human α3, β4, and α5 (D and N variants) subunits were expressed in Xenopus laevis oocytes and tested with or without LYPD6B. We used the 2-electrode voltage-clamp method to quantify responses to acetylcholine (ACh): agonist sensitivity (EC50), maximal agonist-induced current (Imax), and time constant (τ) of desensitization. For β4-α3-α3-β4-α3 and β4-α3-β4-α3-α3, LYPD6B decreased EC50 from 631 to 79 μM, reduced Imax by at least 59%, and decreased τ. For β4-α3-α5D-β4-α3 and β4-α3-β4-α-α5D, LYPD6B decreased Imax by 63 and 32%, respectively. Thus, LYPD6B acted only on (α3)3(β4)2 and (α3)2(α5D)(β4)2 and did not affect the properties of (α3)2(β4)3, α7, or (α3)2(α5N)(β4)2 nAChRs. Therefore, LYPD6B acts as a mixed modulator that enhances the sensitivity of (α3)3(β4)2 nAChRs to ACh while reducing ACh-induced whole-cell currents. LYPD6B also negatively modulates α3β4 nAChRs that include the α5D common human variant, but not the N variant associated with nicotine dependence.
authors.affiliation: *Neuroscience Graduate Program, Department of Neurological Sciences, University of Vermont, Burlington, Vermont, USA; and Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona, USA.
authors.forename: Vanessa
authors.initials: V
authors.lastname: Ochoa
authors.affiliation: *Neuroscience Graduate Program, Department of Neurological Sciences, University of Vermont, Burlington, Vermont, USA; and Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona, USA.
authors.forename: Andrew A
authors.initials: AA
authors.lastname: George
authors.affiliation: *Neuroscience Graduate Program, Department of Neurological Sciences, University of Vermont, Burlington, Vermont, USA; and Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona, USA rnishi@mbl.edu.
authors.forename: Rae
authors.initials: R
authors.lastname: Nishi
authors.affiliation: *Neuroscience Graduate Program, Department of Neurological Sciences, University of Vermont, Burlington, Vermont, USA; and Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona, USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Whiteaker
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D006801:Humans; D009538:Nicotine / Q000494:pharmacology; D009865:Oocytes / Q000187:drug effects / Q000378:metabolism; D021122:Protein Subunits / Q000378:metabolism; D011978:Receptors, Nicotinic / Q000378:metabolism*; D055293:Receptors, Urokinase Plasminogen Activator / Q000378:metabolism*; D014982:Xenopus laevis / Q000378:metabolism
chemical_list: D021122:Protein Subunits; D011978:Receptors, Nicotinic; D055293:Receptors, Urokinase Plasminogen Activator; C403530:nicotinic receptor alpha3beta4; D009538:Nicotine; D000109:Acetylcholine
keywords: CHRNA5; LYNX1; LYNX2; Ly6/uPAR; PSCA